Home Nav
Nextech Invest Logo

Thilo Schroeder

Alfred Scheidegger

Prior to joining Nextech Invest in 2012, Dr Schroeder focused on research specializing on the development of novel cancer therapies in various roles at the University of Zurich, Switzerland, at Micromet Ltd. in Munich, Germany, (now Amgen) as well as during his studies at the University of Sydney, Australia. Dr Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ: BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ: TCON). He holds a PhD in biochemistry from the University of Zurich, Switzerland, an MSc in biotechnology from the École de Supérieure de Biotechnologie de Strasbourg, France and a BSc in biology from the Technical University of Darmstadt, Germany. 

Mr. Schroeder is responsible for the following Nextech portfolio companies:

Peloton Therapeutics, Kura Oncology, ImaginAb, Blueprint Medicines

 

Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

06.09. – 09.09.2017

Mainz/Frankfurt, Germany

  • 25.07.2017

    Santen and TRACON announce initiation of a phase IIa...

  • 18.07.2017

    Kura Oncology announces issuance of U.S. patent for...

  • 13.07.2017

    Kura Oncology establishes collaboration with Foundation...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close